Tag
A study finds that GLP-1 drugs are associated with a larger increase in women's employment rates than obtaining a college degree.
Eric Topol highlights a BMJ study showing tirzepatide (Zepbound) reduces cardiovascular events, infections by 36%, and all-cause mortality by 45% compared to sitagliptin in diabetic patients with prior atherosclerotic cardiovascular disease.
The FDA is set to discuss reclassifying peptides for compounding, with telehealth companies like Mochi Health and Hims & Hers preparing to cash in on the anticipated regulatory shift, driven by political influence from HHS Secretary RFK Jr. and the GLP-1 boom.
The article explores how turnkey telehealth services enable virtually anyone—from established companies like JustAnswer to influencers—to sell GLP-1 weight loss drugs online, highlighting the rapid expansion of the digital health market and the role of infrastructure providers.
A study from Southeast University found that GLP-1 drugs like Ozempic reverse depression-like behavior in mice by promoting growth of Lactobacillus delbrueckii, which produces endocannabinoids that reduce stress effects.
A journalist recounts being scammed by an online telehealth service that charged him for unwanted GLP-1 medications and refused refunds, highlighting a broader pattern of consumer fraud in the growing online weight-loss drug market.
The Withings BodyFit smart scale is marketed for GLP-1 users, offering segmented body composition analysis to monitor muscle mass, though the connection is thin; the article explores the broader trend of metabolic health tracking.
Derek Thompson highlights recent medical breakthroughs including an effective GLP-1 drug from Eli Lilly and a promising new pancreatic cancer drug from Revolution Medicines.
The article explains the biochemical mechanism of GLP-1 agonists, including the new drug retatrutide, and how they regulate appetite and energy metabolism by mimicking natural hormones.